TY  - JOUR
AU  - González-López, Tomás J
AU  - Alvarez-Román, María T
AU  - Pascual, Cristina
AU  - Sánchez-González, Blanca
AU  - Fernández-Fuentes, Fernando
AU  - Pérez-Rus, Gloria
AU  - Hernández-Rivas, José A
AU  - Bernat, Silvia
AU  - Bastida, José M
AU  - Martínez-Badas, María P
AU  - Martínez-Robles, Violeta
AU  - Soto, Inmaculada
AU  - Olivera, Pavel
AU  - Bolaños, Estefanía
AU  - Alonso, Rafael
AU  - Entrena, Laura
AU  - Gómez-Nuñez, Marta
AU  - Alonso, Arancha
AU  - Yera Cobo, María
AU  - Caparrós, Isabel
AU  - Tenorio, María
AU  - Arrieta-Cerdán, Esther
AU  - Lopez-Ansoar, Elsa
AU  - García-Frade, Javier
AU  - González-Porras, José R
PY  - 2017
DO  - 10.1111/bjh.14788
UR  - http://hdl.handle.net/10668/11261
T2  - British journal of haematology
AB  - Eltrombopag is a second-line treatment in primary immune thrombocytopenia (ITP). However, its role in secondary ITP is unknown. We evaluated the efficacy and safety of eltrombopag in secondary ITP in daily clinical practice. Eighty-seven secondary ITP...
LA  - en
KW  - efficacy
KW  - eltrombopag
KW  - immune thrombocytopenia
KW  - safety
KW  - thrombopoietin
KW  - Adult
KW  - Aged
KW  - Autoimmune Diseases
KW  - Benzoates
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Hydrazines
KW  - Lymphoproliferative Disorders
KW  - Male
KW  - Middle Aged
KW  - Platelet Count
KW  - Purpura, Thrombocytopenic, Idiopathic
KW  - Pyrazoles
KW  - Receptors, Thrombopoietin
KW  - Retrospective Studies
KW  - Virus Diseases
TI  - Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
TY  - research article
VL  - 178
ER  -